Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

MEBO Metabolic Malodor Survey (international) for Dr Hazen click here
click to Read more/less

survey for ANYONE who identifies with METABOLIC MALODOR

begun : Oct20
end : no ending for now

Regular readers will know that Dr Stan Hazen et al at Cleveland Clinic are developing a TMA-blocker pill, as they proposed in a 2011 paper that TMAO is a factor in CVD. Recently Dr Hazen and colleagues contacted MEBO as they have always thought they could also help with TMAU. This survey is to give them an idea of the 'state of the community'. It is a "version 1". They may not even look (though they have access permission), but it could be useful to give them an overview of the community

MEBO had a zoom call with Dr Hazen and his team in October. Another zoom call is planned when they have time

This is a GOOGLE FORMS survey

short url for survey :

current participants : 113 (update 18dec20)

Monday, September 9, 2019

uBiome restructuring not affecting MEBO study

On September 4th, MEBO received an email from the Research and Collaborations Lead scientist, who has been providing us with ongoing support on the MEBO Clinical Trial, NCT03582826, Microbial Basis of Systemic Malodor and PATM Conditions, a research study funded by a uBiome research grant. In her email, she informs us that on the previous day, uBiome filed for Chapter 11 Bankruptcy protection. She further explains:
uBiome filed for Chapter 11 Bankruptcy protection. This a necessary step in our ongoing restructuring and will allow our business to move forward as a whole. I wanted to ensure you that business is currently continuing as normal, and our laboratory operations will continue.

We are dedicated to continuing our research partnerships as they are an essential element of the future of the company, and I want to emphasize that our support of your ongoing studies will not be affected.

In addition, I asked the uBiome scientist why the new TMA results category was removed from each participant's personal online report, to which she replied:
I am so sorry that it has been removed, I know it was useful for you and the community.

In the last few weeks/months we have been updating Explorer to make sure what we are saying is scientifically valid and can stand up to scrutiny. I am not on the product team so I was not involved in the decision, but the decision to remove that was most likely based on what they felt was substantial scientific evidence to be able to report those results.

She added that she will mention it again to the product team when they make more updates.

At the present time, uBiome continues to offer the same Gut Explorer test used for the above mentioned MEBO clinical trial.

MEBO Dynamics of the Gut Microbiota 
in Idiopathic Malodor Production

This MEBO clinical trial is in its final stages of data analysis and will soon publish the conclusion. Meanwhile, the updates on findings by Irene Gabashvili, PhD., Principal Investigator, can be found in the following posts in the Aurametrix Blog:
  1. Alloprevotella: September 4, 2019
  2. Epulopiscium: August 19, 2019
  3. Friends and Stars: August 14, 2019
  4. PATM and TMAU: August 5, 2019
  5. Feeding microbiomes: July 21, 2019
  6. Blood type: June 2, 2019
  7. First 41 results: November 21, 2018
  8. Press Release: November 28, 2018
  9. What we hope to learn: June 27, 2018
  10. MEBO Microbiome Study: June 215, 2018
  11. Microbes of anti-social odor: March 14, 2018
  12. Crowdsourcing precision medicine: February 23, 2018
We are most grateful to uBiome for their very generous research grant and to Irene for her dedication and leadership in this research study.

María de la Torre
Founder and Executive Director

A Public Charity
MEBO's Blog (English)
El Blog de MEBO (español)
MEBO Brasil - Blog (Portuguese)

SUPPORT THE MEBO MISSION: Click Amazon button at right sidebar of this blog when shopping online for the holidays
at no extra cost to you.
MEBO gets small commission from Amazon.

get New Posts by EMAIL : Enter your email address :

A EURORDIS and NORD Member Organization


Post a Comment